Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 1045-1050

  Hu, Jianwu ^a   Chen, Caiyun ^a   Su, Yuan ^a   Du, Jiao ^a   Qian, Xin ^a   Jin, Yang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cyclooxygenase 2; Lung neoplasm; Metalloproteinases; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; GREEN FLUORESCENT PROTEIN; MATRIX METALLOPROTEINASE; PROTEIN P53; VASCULOTROPIN;

ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; LEWIS CARCINOMA; MOUSE; NONHUMAN; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

EID: 84867279856     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.702     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Brundage MD, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122: 1037-1057, 2002.
3. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
4. Saphir A: Angiogenesis the unifying concept in cancer. J Natl Cancer Inst 89: 1658-1659, 1995.
5. Chen HJ, Treweeke AT, Ke YQ, West DC and Toh CH: Angiogenically active vascular endothelial growth factor is overexpressed in malignant human and rat prostate carcinoma cells. Br J Cancer 82: 1694-1701, 2000.
6. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA and Swift RI: VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 3: 420-427, 2001.
7. Nishida N, Yano H, Komai K, Nishida T, Kamura T and Kojiro M: Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101: 1364-1374, 2004.
8. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, Watanabe Y and Sasaki T: Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2: 1411-1416, 1996.
9. Jin Y, Xiong X, Su Y, Hu J and Tao X: Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer and its relations to the micrometastasis in peripheral blood. J Huazhong Univ Sci Technolog Med Sci 29: 462-465, 2009.
10. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y and Hirohashi S: Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6: 2431-2439, 2000.
11. Smith WL and Langenbach R: Why there are two cyclooxygenase isozymes. J Clin Invest 107: 1491-1495, 2011.
12. Lim SC, Park SY and Do NY: Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep 10: 1073-1079, 2003.
13. Von Rahden BH, Stein HJ, Pühringer F, Koch I, Langer R, Piontek G, Siewert JR, Höfler H and Sarbia M: Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 65: 5038-5044, 2005.
14. Cianchi F, Cortesini C, Bechi P, Fantappiè O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R and Masini E: Up-regulation of cyclooxygenase-2 gene expression correlates with tumour angiogenesis in human colorectal cancer. Gastroenterology 121: 1339-1347, 2001.
15. Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML and Lin JT: Cyclooxygenase-2 increases hypoxia inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 12: 229-241, 2005.
16. Dirim A, Haberal AN, Goren MR, Tekin MI, Peskircioglu L, Demirhan B and Ozkardes H: VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int Urol Nephrol 40: 861-868, 2008.
17. Kim HS, Youm HR, Lee JS, Min KW, Chung JH and Park CS: Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer 42: 163-170, 2003.
18. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9: 267-285, 2005.
19. Rooprai HK, Rucklidge GJ, Panou C and Pilkington GJ: The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumor cells. Br J Cancer 82: 52-55, 2003.
20. Lee KS, Min KH, Kim SR, Park SJ, Park HS, Jin GY and Lee YC: Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am J Respir Crit Care Med 174: 161-170, 2006.
21. Zilfou JT and Lowe SW: Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol1: a001883. doi: 10.1101/cshperspect.a001883, 2009
22. Mukhopadhyay D, Tsiokas L and Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55: 6161-6165, 1995.
23. Birk DM, Barbato J, Mureebe L and Chaer RA: Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 42: 517-530, 2008.
24. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
25. Fujio Y and Walsh K: Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274: 16349-16354, 1999.
26. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ and Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172-181, 1996.
27. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T and Kanetake H: Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9: 1741-1749, 2003.
28. Wu G, Mannam AP, Wu J, Kirbis S, Shie JL, Chen C, Laham RJ, Sellke FW and Li J: Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol 285: 2420-2429, 2003.
29. Wu G, Luo J, Rana JS, Laham R, Sellke FW and Li J: Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69: 512-519, 2006.
30. Zhang A, Meng L, Wang Q, Xi L, Chen G, Wang S, Zhou J, Lu Y and Ma D: Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep 15: 831-836, 2006.
31. Yao JS, Chen Y, Zhai W, Xu K, Young WL and Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration. Circ Res 95: 364-371, 2004.
32. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL and Gatter KC: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4: 3017-3024, 1998.
33. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT and Harris CC: Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 78: 233-239, 1998.
34. Cava Zzola LT, Rosa A R, Schirmer CC, Gurski R R, Telles JP, Mielke F, Meurer L, Edelweiss MI and Kruel CD: Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma. Rev Col Bras Cir 36: 24-34, 2009.